Abstract
The incretin effect denominates the phenomenon that oral glucose elicits a higher insulin response than intravenous glucose. Glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide are the principal hormones responsible for incretin effect. In patients with type 2 diabetes the incretin effect of these hormones is Impaired. Therapeutic approaches for enhancing the incretin action include degradation resistant GLP-1 receptor agonists (incretin mimetics) and inhibitors of dipeptidyl peptidase-IV (DLP-IV) activity (incretin enhancers-gliptins). These groups of medications have similar efficacy with regards to glycaemic improvement (reduction of HbA1c between 0.5 to 1.1%) and have side-effects like nausea. The incretin mimetics are injectable agents and are more likely to reduce weight or be weight neutral when compared to the oral gliptins. Long-term studies are essential to determine the real potential and role of these newer agents in the management of type 2 diabetes.
Original language | English |
---|---|
Pages (from-to) | 373-383+388 |
Journal | Journal of the Indian Medical Association |
Volume | 106 |
Issue number | 6 |
Publication status | Published - Jun 2008 |
Externally published | Yes |
Keywords
- Dipeptidyl peptidase-IV (DPP-IV) inhibitors
- Glucagon like peptide-1 (GLP-1)
- Incretin
- Type 2 diabetes
ASJC Scopus subject areas
- General Medicine